WO2000013696A1 - Composition pour ameliorer les capacites mentales chez les mammiferes - Google Patents

Composition pour ameliorer les capacites mentales chez les mammiferes Download PDF

Info

Publication number
WO2000013696A1
WO2000013696A1 PCT/IN1999/000036 IN9900036W WO0013696A1 WO 2000013696 A1 WO2000013696 A1 WO 2000013696A1 IN 9900036 W IN9900036 W IN 9900036W WO 0013696 A1 WO0013696 A1 WO 0013696A1
Authority
WO
WIPO (PCT)
Prior art keywords
agents
composition
extract
becoppa
monnieri
Prior art date
Application number
PCT/IN1999/000036
Other languages
English (en)
Inventor
Maharaj Krishen Pandita
Govind Prashad Dubey
Original Assignee
Maharaj Krishen Pandita
Govind Prashad Dubey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN146DE1999 external-priority patent/IN191484B/en
Priority claimed from IN220DE1999 external-priority patent/IN191695B/en
Application filed by Maharaj Krishen Pandita, Govind Prashad Dubey filed Critical Maharaj Krishen Pandita
Priority to EP99940453A priority Critical patent/EP1039919A1/fr
Priority to CA002306165A priority patent/CA2306165A1/fr
Priority to JP2000568504A priority patent/JP2002524419A/ja
Priority to AU54425/99A priority patent/AU742556B2/en
Publication of WO2000013696A1 publication Critical patent/WO2000013696A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to a composition for improving mental capabilities in children, adults and mentally deficient people.
  • the composition of the present invention is advantageously used for improving short term memory, long term memory and attention span, by exerting its effect on increasing concentration ability, increasing short term and long term memory span, improving learning ability, speech & recall defects and improving overall mental performance.
  • Brahmi herb has memory enhancement activity.
  • Brahmi Herb refers to an herbal composition consisting of the whole plants, plant parts, or extracts of Becoppa monnieri and/ or Centella asiaticia, both of which can be found growing in wet climates throughout the tropical zones of India. Highest yield was found in valley of Brahmaputra, Assam and West Bengal. It is also known that Becoppa monnieri / Centella asiatica can be processed to obtain either a hydro, hydro-alcoholic or alcoholic extract, and that the herb itself or any of the above extracts may be used for memory enhancement.
  • Herb and herbal extracts of Acorus calamus are also known in the art for memory enhancement.
  • such extracts known in the art contain ⁇ - asarone present in an amount of about 500-700 ppm.
  • a disadvantage associated with the known Acorus calamus is the presence of ⁇ -asarone, which has carcinogenic properties.
  • Acorus calamus is found in Jerusalem, Punjab, Himachal Pradesh and Madhya Pradesh.
  • Extract of Celestrus paniculatus oil is used for reduction in hyper activity of the brain thus permits the nerves to retain the information process for improving the memory.
  • Memory is a complex process regulated by various factors viz. anxiety, reaction, derangement of neuron transmitters, particularly acetylecheline including seroyrotimine are responsible of the regulation of memory. Malnutrition, particularly, iodine deficiency, protein deficiency also play a significant role in memory regulation.
  • the object of this invention is therefore, to propose a highly potent composition for improving overall mental performance i.e. long term memory, short term memory, attention span, its retention, recall and speech defects by arresting the loss of acstylcholine, increasing capabilities of neurons to retain information, decreasing the hyperexcitability of nervous system in the brain by reducing catecholiamine level, reducing emotional fluctuation by regulating 5 HT in the brain.
  • the second object of this invention is to prevent the presence of ⁇ - asarone, in quantities of > 5 ppm in Acorus calamus, which makes the composition safer and free from side effects.
  • this invention provides a highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil.
  • the said highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people in 10ml/ 1 lgms characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil in the amounts as given below:
  • Celestrus paniculatus oil - about 0.02-0.2 ml and the balance amount, if any, is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • This composition will have excellent properties of improving the overall mental performance, for instance, a child having lower memory due to higher level of anxiety and aggressiveness, the Centella asiatica in the composition will decrease serotonine and thereby reduce the anxiety and Celestrus paniculatus oil in the composition will decrease the catecholiamine and thereby reduces the aggressiveness and simultaneously making the other components of the composition active and improve the overall mental performance.
  • the herbal extracts are in the form of a powder, liquid or paste and the quantities used are based on dry powder as given in the composition.
  • Brahmi herb extract is either obtained from Becoppa monnieri or from Centella asiatica or from combination of both.
  • the preferred range of the following herbal material is as follows:
  • Centella asiatica about 25-200 mg
  • the Becoppa monnieri and Centella asiatica used in the composition has preferably saponins content about 15-25%.
  • the Acorus calamus used has preferably about 40-55% glycosides and ⁇ -asarone content below 5 ppm.
  • Becoppa monnieri extract and Centella asiatica are hydro-alcoholic organic extracts.
  • the said Acorus calamus extract is hydro-alcoholic extract of the Rhizone of the herb and the extraction technique is adopted to either eliminate the ⁇ -asarone for obtaining extract of Acorus calamus or with ⁇ -asarone less than 5 ppm and the contents of ⁇ -asarone in the extract is measured by gas chromatography recommended by FDA, USA
  • the extract of Celestrus paniculatus oil is an oil extract.
  • the extract of Becoppa monnieri for use in the composition is either prepared by any known process or by refluxing an alcoholic extract of Becoppa monnieri, concentrating to a solid content of about 50-70% and drying the refluxed material at temperature about 50-90°C under vacuum, treating the dried material with organic solvent preferably chloroform for removal of the soluble fraction and then subjecting the insoluble fraction to refining to obtain a debitterized rich fraction of glycosides.
  • the said composition is in a powder, tablet, capsule, syrup or in suspension form and also is delivered through any other known carriers such as biscuits/snacks.
  • Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
  • the Nootropic components present in the composition improves short term memory, long term memory and attention span, by exerting its effect on increasing concentration ability, increasing memory span, improving learning ability and overall mental performance.
  • the activity of each of such constituents when present in combination has been ascertained and tests have shown that better levels of enhancement of memory facets are obtained where both the constituents are present in the composition.
  • the nootropic & psychotropic properties are achieved.
  • the composition includes only Becoppa monnieri.
  • the composition contains both Becoppa monnieri and Centella asiatica.
  • the extract of Shatparvika comprises Acorus calamus and should have glycosides present in the range of about 35 to 65%. Preferably, but without implying any limitation to the scope of the invention, about 40-55% of glycosides is present in the Acorus calamus. Further, ⁇ -asarone present in Acorus calamus should not exceed to more than 5 ppm. Acorus calamus is responsible for recall and expression of the stored information from the brain.
  • the extract is hydro-alcoholic extract of the Rhizome of the herb Acorus calamus and the extraction technique is adopted to either eliminate the ⁇ - asarone for obtaining extract of Acorus calamus or with ⁇ -asarone ⁇ 5 ppm.
  • the extract of Vadangul used in the present invention comprises
  • the composition contains about 100-500 mg of Becoppa monnieri and preferably between 150- 300 mg. If less than 150 mg is present the efficacy of the composition is adversely affected, and desired results can not be obtained. If the composition contains more than 300 mg no additional activity is achieved. In fact, if the composition contains excessively high amount of Becoppa monnieri, such as more than 2000 mg the gastric irritation has been observed.
  • Centella asiatica is present.
  • the composition contains about 25-200 mg of Centella asiatica.
  • Such a composition also contains about 7.5 - 25 mg of Acorus calamus and preferably about 8.0 to 20 mg.
  • the composition contains about 0.02 to 0.20 ml and preferably about 0.04 to 0.15 ml of Celestrus paniculatus oil.
  • the composition may be in a powder, tablet, capsule, syrup or suspension form.
  • an alcoholic or hydro-alcoholic extract of Becoppa monnieri prepared by the process of the present invention and as described subsequently herein is employed in the composition, as the bitter constituents are removed therefrom.
  • a particular and advantageous . application is with respect to a syrup form, as a bitter palatable taste ought to be avoided.
  • the hydro-alcoholic extract of Becoppa monnieri of the process of the present invention is used in the composition.
  • the starting material comprises an alcoholic extract of Becoppa monnieri and Centella asiatica, which is refluxed till the herb is exhausted and so as to obtain an extract having glycosides and other compounds certain of which are bitter and undesirable constituents.
  • the refluxed material is concentrated to have a solid content of about 50-70% under vacuum conditions and that the operating temperature is between 50-70°C.
  • the concentrated product is dried at a temperature of about 50-90°C. It has been found that if higher temperature is employed it would then destroy or change the nature of palatable and active glycosides contained in the extract.
  • the step of drying may be effected in a drum or tray dryer under vacuum at a temperature of about 50 to 90°C,and preferably about 50- 70°C so as to prevent any thermal damage to the palatable glycosides and to obtain a powdered form of the extract.
  • the step of spraying drying may be effected in a spray dryer.
  • the step of drying is carried out for a period of about 40 to 120 sees and preferably for a period of about 60 to 80 sec. If the step of drying is effected in a tray or drum dryer, the step of milling them follows the step of drying. In the instance of spray drying, the operating temperature should preferably be between 70 to 80°C.
  • the dried extract is subjected to the step of solubilising in solvents namely chloroform.
  • the extracts are soluble in other solvents rather than chloroform, which are preferably not employed, as certain of the bitter constituents present in the extract are also soluble in such other solvents.
  • the step of solubilising is preferably carried out in chloroform as a solvent under atmospheric condition to obtain a soluble fraction and an insoluble fraction.
  • the soluble fraction is rejected and such a process may be repeated for refinement of the insoluble fraction.
  • the insoluble fraction is filtered and concentrated at about 50-70°C under vacuum and then dried also at a temperature not exceeding 70°C.
  • the dried powder is subjected to the step of refinement, which comprises in a first step of dissolving the said powder in water to obtain a soluble fraction.
  • the soluble fraction is filtered and concentrated to about 50- 70% solids under vacuum.
  • the step of refining consists in a second step and wherein the concentrated solids obtained from the first step of refining is dissolved in alcohol to obtain an alcohol soluble fraction and a second insoluble fraction.
  • the alcohol soluble fraction is concentrated under vacuum at a temperature of about 50-70°C to obtain a concentrated powder to about 50-70% solid of content.
  • the step of refinement comprises in a third step, wherein the alcohol soluble fraction is dissolved in acetone to obtain a first fraction containing acetone soluble material and a second fraction insoluble in acetone and comprising debitterized glycocidic rich fraction, which is also subjected to the step of concentration and then finally dried at a temperature of about 50 to 70°C.
  • the step of drying may be effected after each step of refinement or only after the third step of refinement.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 120 mg of the alcoholic extract of Becoppa monnieri about 15 mg of extract of Centella asiatica, about 15 mg of ⁇ -asarone free extract of Acorus calamus, about 0.03 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, - about 22 mg of ⁇ -asarone free extract of Acorus calamus, about 0.15 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • a 10 ml composition in the form of syrup contained the following active ingredients: - about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 22 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • active ingredients - about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 22 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • a 10 ml composition in the form of syrup contained the following active ingredients: - about 200 mg of the alcoholic extract of Becoppa monnieri about 25 mg of ⁇ -asarone free extract of Acorus calamus, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosage Children upto 5 years about 5 ml - two times a day
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • composition II exhibited marked improvement in nootropic properties. However, the degree of improvement was lesser than composition II. In the absence of Centella asiatica no psychotropic activity could be identified.
  • composition was beneficial for short term, long term and improvement in the attention span.
  • degree of significance noted was p ⁇ 0.02.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri . - about 25 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage: Children upto 5 years about 5 ml - two times a day
  • compositions can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • the composition exhibited marked improvement in nootropic properties. However, the degree of improvement was lesser than composition II. In the absence of Centella asiatica no psychotropic activity could be identified. However, the composition was beneficial for short term, long term and improvement in the attention span.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of extract of Centella asiatica, about 25 mg of ⁇ -asarone free extract of Acorus calamus, - about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosage Children upto 5 years about 5 ml - two times a day
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Centella asiatica - about 25 mg of ⁇ -asarone free extract of Acorus calamus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • active ingredients about 200 mg of the alcoholic extract of Centella asiatica - about 25 mg of ⁇ -asarone free extract of Acorus calamus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosage Children upto 5 years about 5 ml - two times a day
  • EXAMPLE VDT 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 0.15 ml of extracted oil of Celestrus peniculatus and the balance amount is from known additives selected from stabilizers, a ⁇ ti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage:
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of extract of Centella asiatica, about 0.15 ml of extracted oil of Celestrus peniculatus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosage Children upto 5 years about 5 ml - two times a day
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • the brahmi herb (Becoppa monnieri / Centella asiatica) as a complete plant was dried and extracted with absolute Ethanol in a Stainless Steel Pan. Four parts of Ethanol was mixed with one part of Herb and the material refluxed for about 10-12 hours. The process was repeated about 6 times till the herb is exhausted. All the above 6 extractions were concentrated to a paste of about 80% solids. This was done under vacuum and the solvents were recovered. The material was dried under reduced pressure at a temperature of about 50°C in a vacuum drum drier. The powder obtained was extracted with pure chloroform (6 times) to remove the alkalides and oils. Identity test for alkaloids was performed. The material was filtered and chloroform insoluble fraction was concentrated to about 70% solids.
  • the residue was dried in a vacuum drum drier.
  • the dried powder was dissolved in about 6 times the quantity of distilled water and filtered.
  • the supernatant was reduced to about 80% solids under vacuum and dissolved in pure Ethyl alcohol.
  • the alcohol soluble fraction was reduced to about 80% solids under vacuum and dissolved in about 4 times the quantity of acetone.
  • the acetone insoluble fraction was dried in drum drier.
  • the dried powder was glycocidal rich fraction and debitterized extract of Brahmi herb. Identity test and quantitative analysis of saponins (Tritrepenic glycocides) was conducted. This fraction had saponin content of above about 15% to 20%.
  • Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
  • composition is in the form of biscuits or snacks, each unit should contain the active ingredients as specified in the aforesaid examples.
  • composition described and claimed is based on the herbal extracts in powder form and in the case Celestrus paniculatis in oil form. However, if the composition is made in liquid form, the extract described can also be used in paste / liquid form and the quantities calculated on the dry matter content corresponding to above composition.
  • Celestrus paniculatus oil is brought into water soluble phase by using Tween-20 or any such known emulsifying agent.
  • composition described above is useful for treating the diseases which cause the mental incapabilities such as lower cholinergic activity, lower level of protein synthesis, presence of higher level of catechaliamine, improper functioning of 5 FIT in the brain, lower I.Q. level i.e. 70-50 and mental retardation caused by the following factors: - health of mother genetic disease; chromosomal diseases; maternal illness; anemia; - cardio-pulmonary diseases; hemorrhage and hypertension; malnutrition and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition très puissante, à base d'herbes médicinales, utilisée pour augmenter les performances mentales chez les enfants, les adultes et les personnes ayant une déficience mentale. Ladite composition se caractérise en ce qu'elle est constituée de matières végétales actives extraites de l'herbe appelée Brahmi, d'au moins une des herbes de celestrus paniculatus et de l'huile d'acorus calamus.
PCT/IN1999/000036 1998-09-07 1999-08-09 Composition pour ameliorer les capacites mentales chez les mammiferes WO2000013696A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99940453A EP1039919A1 (fr) 1998-09-07 1999-08-09 Composition pour ameliorer les capacites mentales chez les mammiferes
CA002306165A CA2306165A1 (fr) 1998-09-07 1999-08-09 Composition pour ameliorer les capacites mentales chez les mammiferes
JP2000568504A JP2002524419A (ja) 1998-09-07 1999-08-09 哺乳類において精神能力を改善するための組成物
AU54425/99A AU742556B2 (en) 1998-09-07 1999-08-09 Composition for improving mental capabilities in mammals

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
IN2660/DEL/98 1998-09-07
IN2660DE1998 1998-09-07
IN2658DE1998 1998-09-07
IN2658/DEL/98 1998-09-07
IN146/DEL/99 1999-01-25
IN146DE1999 IN191484B (fr) 1999-01-25 1999-01-25
IN220/DEL/99 1999-02-10
IN220DE1999 IN191695B (fr) 1999-02-10 1999-02-10
IN221/DEL/99 1999-02-10
IN222DE1999 1999-02-10
IN222/DEL/99 1999-02-10
IN221DE1999 1999-02-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09554026 A-371-Of-International 2000-10-27
US10/346,290 Continuation US20030157201A1 (en) 1998-09-07 2003-01-16 Composition for improving mental capabilities in mammals

Publications (1)

Publication Number Publication Date
WO2000013696A1 true WO2000013696A1 (fr) 2000-03-16

Family

ID=27547440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN1999/000036 WO2000013696A1 (fr) 1998-09-07 1999-08-09 Composition pour ameliorer les capacites mentales chez les mammiferes

Country Status (6)

Country Link
EP (1) EP1039919A1 (fr)
JP (1) JP2002524419A (fr)
CN (1) CN1277555A (fr)
AU (1) AU742556B2 (fr)
CA (1) CA2306165A1 (fr)
WO (1) WO2000013696A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003813A1 (fr) * 2000-07-12 2002-01-17 Raj Kumar, Sujatha Utilisation de saponines de triterpenoide de type dammarane
WO2002003996A1 (fr) * 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Utilisation de saponines de triterpenoide de type dammarane
WO2003068251A1 (fr) * 2002-02-14 2003-08-21 Dalmia Centre For Research And Development Formulation a base d'herbes medicinales destinee a traiter des troubles deficitaires de l'attention (dca/thada) et procede de preparation correspondant
DE102006033321A1 (de) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medizinische Verwendung von N-Phenylpropenoyl-Aminosäurederivaten und verwandten Verbindungen
EP4035538A1 (fr) * 2021-01-29 2022-08-03 Eva Süssmann Composition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0318686A (pt) * 2003-12-26 2006-12-26 Council Scient Ind Res formulação de ervas contendo centella asiatica e sesamum indicum como tonico cerebral
CN1303098C (zh) * 2004-12-09 2007-03-07 中国人民解放军第二军医大学 假马齿苋皂苷化合物、总皂苷及其在医药中的应用
CN1833692B (zh) * 2005-03-15 2010-08-11 成都华高药业有限公司 一种假马齿苋提取物及其制备方法和用途
CN103393733A (zh) * 2013-08-19 2013-11-20 广西中医药大学 积雪草有效部位及其应用
SG10201507607RA (en) * 2015-09-14 2017-04-27 Moleac Pte Ltd Process For Producing Traditional Chinese Medicine Compositions, And Compositions Obtainable By The Process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0358939A (ja) * 1989-07-27 1991-03-14 Toreede Uindo Kk 老化防止食品及びその製造法
GB2314270A (en) * 1996-06-20 1997-12-24 M S Raptakos Brett & Co Ltd Anti-AIDS Ayurvedic medicine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0358939A (ja) * 1989-07-27 1991-03-14 Toreede Uindo Kk 老化防止食品及びその製造法
GB2314270A (en) * 1996-06-20 1997-12-24 M S Raptakos Brett & Co Ltd Anti-AIDS Ayurvedic medicine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 15, no. 206 27 May 1991 (1991-05-27) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003813A1 (fr) * 2000-07-12 2002-01-17 Raj Kumar, Sujatha Utilisation de saponines de triterpenoide de type dammarane
WO2002003996A1 (fr) * 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Utilisation de saponines de triterpenoide de type dammarane
WO2003068251A1 (fr) * 2002-02-14 2003-08-21 Dalmia Centre For Research And Development Formulation a base d'herbes medicinales destinee a traiter des troubles deficitaires de l'attention (dca/thada) et procede de preparation correspondant
DE102006033321A1 (de) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medizinische Verwendung von N-Phenylpropenoyl-Aminosäurederivaten und verwandten Verbindungen
EP4035538A1 (fr) * 2021-01-29 2022-08-03 Eva Süssmann Composition

Also Published As

Publication number Publication date
AU742556B2 (en) 2002-01-03
JP2002524419A (ja) 2002-08-06
CN1277555A (zh) 2000-12-20
EP1039919A1 (fr) 2000-10-04
CA2306165A1 (fr) 2000-03-16
AU5442599A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
US4966893A (en) Method for treatment of senile dementia
US20020146467A1 (en) Herbal composition for the prevention and treatment of dementia
EP2057994A1 (fr) Préparation d'extrait de cactus à figues
KR100382564B1 (ko) 치매병 예방 및 치료용 생약조성물
AU742556B2 (en) Composition for improving mental capabilities in mammals
EP0370284B1 (fr) Composition contenant un extrait obtenu par extraction à l'aide d'un solvant organique aqueux et procédé de préparation à cet effet
US7514104B2 (en) Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory
KR100450021B1 (ko) 4'-0-메틸피리독신 및 바이오플라본 함량을 감소시킨 징코 빌로바 잎 추출물 및 제조 방법
JP3968405B2 (ja) 抗アレルギー剤
JPH07274894A (ja) 胃潰瘍予防飲食品
JP5721353B2 (ja) 胆汁酸分泌促進剤
US5741491A (en) Medicinal composition for diabetes
JP3334725B2 (ja) 体内アルコール、その代謝物の低下促進剤及び口中清涼剤
KR101082938B1 (ko) 수용성 비타민이 인리치먼트된 비타민제 조성물 및 이의 제조 방법
KR101071684B1 (ko) 팔각회향 추출물을 유효성분으로 포함하는 기억력 및 학습 능력 증진용 조성물
KR101049493B1 (ko) 정력자 추출물을 유효성분으로 포함하는 기억력 및 학습 능력 증진용 조성물
US5501866A (en) Product and method for inhibiting caffeine stimulation with theanine
KR101043212B1 (ko) 뇌 기능 개선용 건강기능식품
US20030157201A1 (en) Composition for improving mental capabilities in mammals
US6159986A (en) Compounds and therapy for resisting memory loss in humans
KR101317320B1 (ko) 청호 추출물을 유효성분으로 포함하는 기억력 및 학습 능력 증진용 조성물
KR100512912B1 (ko) 알코올대사 생약 촉진제
KR20150093141A (ko) 생약재의 추출물을 유효성분으로 포함하는 뇌질환 또는 신경질환의 예방 또는 치료용 조성물
KR100500029B1 (ko) 숙지황 추출물을 포함하는 기억력 향상 생약조성물
US20190030087A1 (en) Composition Comprising an Extract of Liriopsis Tuber for Protecting Brain Cells and Improving Memory

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99801531.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2306165

Country of ref document: CA

Ref document number: 2306165

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999940453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 54425/99

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1999940453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09554026

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 54425/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999940453

Country of ref document: EP